{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:42:44Z","timestamp":1775562164623,"version":"3.50.1"},"reference-count":17,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"DOI":"10.1182\/bloodadvances.2023010636","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T20:51:36Z","timestamp":1698094296000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-0447","authenticated-orcid":false,"given":"Alexander","family":"Spira","sequence":"additional","affiliation":[{"name":"2Virginia Cancer Specialists Research Institute, Fairfax, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7992-637X","authenticated-orcid":false,"given":"Xiaolei","family":"Zhou","sequence":"additional","affiliation":[{"name":"3RTI Health Solutions, Research Triangle Park, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Liao","sequence":"additional","affiliation":[{"name":"4ADC Therapeutics America Inc, Murray Hill, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"4ADC Therapeutics America Inc, Murray Hill, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"5NIHR Clinical Research Facility, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyun","family":"Ai","sequence":"additional","affiliation":[{"name":"6Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-5623","authenticated-orcid":false,"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"7Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirit M.","family":"Ardeshna","sequence":"additional","affiliation":[{"name":"8Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hess","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-0464","authenticated-orcid":false,"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"10Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"11Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"12Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"13Department of Oncology and Hematology, Humanitas Research Hospital\u2212IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan Pablo","family":"Alderuccio","sequence":"additional","affiliation":[{"name":"14Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"15Division of Oncology, Washington University, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"4ADC Therapeutics America Inc, Murray Hill, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajuan","family":"Qin","sequence":"additional","affiliation":[{"name":"4ADC Therapeutics America Inc, Murray Hill, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiying Cindy","family":"Xu","sequence":"additional","affiliation":[{"name":"4ADC Therapeutics America Inc, Murray Hill, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"16IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Ser\u00e0gnoli, Bologna, Italy"},{"name":"17Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"issue":"16","key":"2024010914085443000_bib1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2024010914085443000_bib2","doi-asserted-by":"crossref","first-page":"20406207221087511","DOI":"10.1177\/20406207221087511","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data","volume":"13","author":"Furqan","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2024010914085443000_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.32526","article-title":"Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure","volume":"126","author":"Ayers","year":"2020","journal-title":"Cancer"},{"key":"2024010914085443000_bib4","volume-title":"ZYNLONTA\u00ae (loncastuximab tesirine-lpyl). Package insert","year":"2022"},{"key":"2024010914085443000_bib5","author":"Swedish Orphan Biovitrum AB","year":"2023"},{"key":"2024010914085443000_bib6","author":"Swedish Orphan Biovitrum AB","year":"2023"},{"issue":"6","key":"2024010914085443000_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024010914085443000_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clml.2021.09.001","article-title":"Health-related quality of life, symptoms, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"22","author":"Spira","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2024010914085443000_bib9","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2021-152798","article-title":"Real-world health-related quality of life in patients with diffuse large B-cell lymphoma: comparisons with reference populations and by line of therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024010914085443000_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00277-021-04689-4","article-title":"Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study","volume":"101","author":"Paunescu","year":"2022","journal-title":"Ann Hematol"},{"issue":"10","key":"2024010914085443000_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ajh.24819","article-title":"Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma","volume":"92","author":"Saygin","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"2024010914085443000_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients","volume":"26","author":"Di","year":"2021","journal-title":"Oncologist"},{"issue":"27","key":"2024010914085443000_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024010914085443000_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"2024010914085443000_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","article-title":"Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-cell lymphoma","volume":"29","author":"Westin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024010914085443000_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024010914085443000_bib17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/14737140.2021.1988853","article-title":"Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma","volume":"21","author":"Ahmed","year":"2021","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/93\/2180451\/blooda_adv-2023-010636-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/93\/2180451\/blooda_adv-2023-010636-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:09:32Z","timestamp":1704809372000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/93\/498392\/Clinical-outcomes-of-older-and-younger-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010636","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}